SK Bio Eyes Past And Future Milestones On Development Journey

SK Biopharmaceuticals vice-president Haein Shin talks to Scrip about the company’s long journey to developing and launching novel innovative CNS drugs in global markets and what is behind its achievement, which is seen as unprecedented in the South Korean pharma industry.

SK Biopharmaceuticals
SK Bio Aiming To Become Top 50 Global Pharma By 2025 • Source: SK Biopharmaceuticals

More from South Korea

More from Focus On Asia